1. Home
  2. AGIO vs EVH Comparison

AGIO vs EVH Comparison

Compare AGIO & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • EVH
  • Stock Information
  • Founded
  • AGIO 2007
  • EVH 2011
  • Country
  • AGIO United States
  • EVH United States
  • Employees
  • AGIO N/A
  • EVH N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • EVH Other Consumer Services
  • Sector
  • AGIO Health Care
  • EVH Consumer Discretionary
  • Exchange
  • AGIO Nasdaq
  • EVH Nasdaq
  • Market Cap
  • AGIO 1.4B
  • EVH 1.2B
  • IPO Year
  • AGIO 2013
  • EVH 2015
  • Fundamental
  • Price
  • AGIO $27.66
  • EVH $8.96
  • Analyst Decision
  • AGIO Buy
  • EVH Strong Buy
  • Analyst Count
  • AGIO 8
  • EVH 14
  • Target Price
  • AGIO $56.57
  • EVH $16.64
  • AVG Volume (30 Days)
  • AGIO 745.1K
  • EVH 2.4M
  • Earning Date
  • AGIO 05-01-2025
  • EVH 05-08-2025
  • Dividend Yield
  • AGIO N/A
  • EVH N/A
  • EPS Growth
  • AGIO N/A
  • EVH N/A
  • EPS
  • AGIO 11.64
  • EVH N/A
  • Revenue
  • AGIO $36,498,000.00
  • EVH $2,554,741,000.00
  • Revenue This Year
  • AGIO $41.13
  • EVH N/A
  • Revenue Next Year
  • AGIO $234.96
  • EVH $16.02
  • P/E Ratio
  • AGIO $2.38
  • EVH N/A
  • Revenue Growth
  • AGIO 36.07
  • EVH 30.09
  • 52 Week Low
  • AGIO $23.42
  • EVH $8.35
  • 52 Week High
  • AGIO $62.58
  • EVH $33.63
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 44.94
  • EVH 38.97
  • Support Level
  • AGIO $26.87
  • EVH $9.31
  • Resistance Level
  • AGIO $28.24
  • EVH $10.12
  • Average True Range (ATR)
  • AGIO 1.94
  • EVH 0.57
  • MACD
  • AGIO 0.22
  • EVH -0.07
  • Stochastic Oscillator
  • AGIO 66.15
  • EVH 20.50

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Share on Social Networks: